ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Anova Innovation Limited
Anova Innovation Limited
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Dragonfly Therapeutics
Engeneic Pty Limited
M.D. Anderson Cancer Center
Ascentage Pharma Group Inc.
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Inhibrx Biosciences, Inc
Tyligand Pharmaceuticals (Suzhou) Limited
Genfleet Therapeutics (Shanghai) Inc.
Laekna Limited
Thomas Jefferson University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Jonsson Comprehensive Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
NRG Oncology
Thomas Jefferson University
ImmunityBio, Inc.
ImmunityBio, Inc.
Columbia University
Nelum Corp
Purple Biotech Ltd.
Vanderbilt-Ingram Cancer Center
Shanghai Zhongshan Hospital
Fudan University
Fox Chase Cancer Center
City of Hope Medical Center
Barbara Ann Karmanos Cancer Institute
Aravive, Inc.
Rutgers, The State University of New Jersey
Qilu Pharmaceutical Co., Ltd.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
Hoosier Cancer Research Network
Chinese PLA General Hospital
HonorHealth Research Institute
MedSIR
Nektar Therapeutics
Corcept Therapeutics
National Cancer Institute (NCI)
Chinese PLA General Hospital
Scandion Oncology A/S
NextCure, Inc.